Last edition
News about "PIK3CA mutations "
Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment
Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.
PIK3CA Mutations | 20/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members